Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

Conditions:   T-cell Acute Lymphoblastic Leukemia;   T-cell Non-Hodgkin Lymphoma Intervention:   Drug: anti-CD5 CAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio Not yet recruiting

Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials